secwatch.observer — SEC 8-K summary
======================================

Issuer:     Revolution Medicines, Inc. (RVMD)
CIK:        0001628171
Form:       8-K
Filed at:   2022-12-07T23:59:59+00:00
Accession:  0001193125-22-300162
Event type: other_material
Sentiment:  negative
Materiality: 0.50
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

Revolution Medicines receives termination notice from Genzyme (Sanofi) for collaboration deal
--------------------------------------------------------------------------------

- Genzyme terminated the June 2018 collaboration agreement for convenience; effective June 4, 2023.
- Notice received December 6, 2022; agreement had been disclosed in prior SEC filings.
- No financial impact or termination fees disclosed in the filing.
- Company may lose expected future collaboration revenue from Sanofi.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628171/000119312522300162/0001193125-22-300162-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628171/000119312522300162/d426724d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-300162

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer